Publication

Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment

Sturkenboom, M. G. G., Simbar, N., Akkerman, O. W., Ghimire, S., Bolhuis, M. S. & Alffenaar, J-W. C., 15-Dec-2018, In : Clinical Infectious Diseases. 67, suppl_3, p. S303-S307 5 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Sturkenboom, M. G. G., Simbar, N., Akkerman, O. W., Ghimire, S., Bolhuis, M. S., & Alffenaar, J-W. C. (2018). Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. Clinical Infectious Diseases, 67(suppl_3), S303-S307. https://doi.org/10.1093/cid/ciy613

Author

Sturkenboom, Marieke G G ; Simbar, Noviana ; Akkerman, Onno W ; Ghimire, Samiksha ; Bolhuis, Mathieu S ; Alffenaar, Jan-Willem C. / Amikacin Dosing for MDR Tuberculosis : A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. In: Clinical Infectious Diseases. 2018 ; Vol. 67, No. suppl_3. pp. S303-S307.

Harvard

Sturkenboom, MGG, Simbar, N, Akkerman, OW, Ghimire, S, Bolhuis, MS & Alffenaar, J-WC 2018, 'Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment', Clinical Infectious Diseases, vol. 67, no. suppl_3, pp. S303-S307. https://doi.org/10.1093/cid/ciy613

Standard

Amikacin Dosing for MDR Tuberculosis : A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. / Sturkenboom, Marieke G G; Simbar, Noviana; Akkerman, Onno W; Ghimire, Samiksha; Bolhuis, Mathieu S; Alffenaar, Jan-Willem C.

In: Clinical Infectious Diseases, Vol. 67, No. suppl_3, 15.12.2018, p. S303-S307.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar J-WC. Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment. Clinical Infectious Diseases. 2018 Dec 15;67(suppl_3):S303-S307. https://doi.org/10.1093/cid/ciy613


BibTeX

@article{4f2b2870ab4b4c0d93644a3e0295751a,
title = "Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment",
abstract = "Background. Amikacin has been used for over 40 years in multidrug resistant tuberculosis (MDR-TB), but there is still debate on the right dose. The aim of this review was to search relevant pharmacokinetic (PK) and pharmacodynamic (PD) literature for the optimal dose and dosing frequency of amikacin in MDR-TB regimens trying to optimize efficacy while minimizing toxicity.Methods. A systematic review on the value of amikacin as second-line drug in the treatment of MDR-TB was performed.Results. Five articles were identified with data on PK, hollow-fiber system model for TB and or early bactericidal activity of amikacin. Despite the long period in which amikacin has been available for the treatment of MDR-TB, very little PK data is available. This highlights the need for more research.Conclusions. Maximum concentration (C-max) of amikacin related to MIC proved to be the most important PK/PD index for efficacy. The target C-max/MIC ratio should be 10 at site of infection. Cumulative area under the concentration-time curve (AUC) corresponding with cumulative days of treatment was associated with an increased risk of toxicity.",
keywords = "pharmacokinetics/pharmacodynamics, optimal dose, Monte Carlo simulation, probability of target attainment, CLEARANCE LIPOSOMAL AMIKACIN, EARLY BACTERICIDAL ACTIVITY, REGIMEN, PHARMACOKINETICS, EXPOSURE, DOSAGE",
author = "Sturkenboom, {Marieke G G} and Noviana Simbar and Akkerman, {Onno W} and Samiksha Ghimire and Bolhuis, {Mathieu S} and Alffenaar, {Jan-Willem C}",
year = "2018",
month = "12",
day = "15",
doi = "10.1093/cid/ciy613",
language = "English",
volume = "67",
pages = "S303--S307",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "suppl_3",

}

RIS

TY - JOUR

T1 - Amikacin Dosing for MDR Tuberculosis

T2 - A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment

AU - Sturkenboom, Marieke G G

AU - Simbar, Noviana

AU - Akkerman, Onno W

AU - Ghimire, Samiksha

AU - Bolhuis, Mathieu S

AU - Alffenaar, Jan-Willem C

PY - 2018/12/15

Y1 - 2018/12/15

N2 - Background. Amikacin has been used for over 40 years in multidrug resistant tuberculosis (MDR-TB), but there is still debate on the right dose. The aim of this review was to search relevant pharmacokinetic (PK) and pharmacodynamic (PD) literature for the optimal dose and dosing frequency of amikacin in MDR-TB regimens trying to optimize efficacy while minimizing toxicity.Methods. A systematic review on the value of amikacin as second-line drug in the treatment of MDR-TB was performed.Results. Five articles were identified with data on PK, hollow-fiber system model for TB and or early bactericidal activity of amikacin. Despite the long period in which amikacin has been available for the treatment of MDR-TB, very little PK data is available. This highlights the need for more research.Conclusions. Maximum concentration (C-max) of amikacin related to MIC proved to be the most important PK/PD index for efficacy. The target C-max/MIC ratio should be 10 at site of infection. Cumulative area under the concentration-time curve (AUC) corresponding with cumulative days of treatment was associated with an increased risk of toxicity.

AB - Background. Amikacin has been used for over 40 years in multidrug resistant tuberculosis (MDR-TB), but there is still debate on the right dose. The aim of this review was to search relevant pharmacokinetic (PK) and pharmacodynamic (PD) literature for the optimal dose and dosing frequency of amikacin in MDR-TB regimens trying to optimize efficacy while minimizing toxicity.Methods. A systematic review on the value of amikacin as second-line drug in the treatment of MDR-TB was performed.Results. Five articles were identified with data on PK, hollow-fiber system model for TB and or early bactericidal activity of amikacin. Despite the long period in which amikacin has been available for the treatment of MDR-TB, very little PK data is available. This highlights the need for more research.Conclusions. Maximum concentration (C-max) of amikacin related to MIC proved to be the most important PK/PD index for efficacy. The target C-max/MIC ratio should be 10 at site of infection. Cumulative area under the concentration-time curve (AUC) corresponding with cumulative days of treatment was associated with an increased risk of toxicity.

KW - pharmacokinetics/pharmacodynamics

KW - optimal dose

KW - Monte Carlo simulation

KW - probability of target attainment

KW - CLEARANCE LIPOSOMAL AMIKACIN

KW - EARLY BACTERICIDAL ACTIVITY

KW - REGIMEN

KW - PHARMACOKINETICS

KW - EXPOSURE

KW - DOSAGE

U2 - 10.1093/cid/ciy613

DO - 10.1093/cid/ciy613

M3 - Review article

VL - 67

SP - S303-S307

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - suppl_3

ER -

ID: 71529950